Pre-clinical studies now evaluating anti-CD20-IFN-α and anti-CD20-IFN-β against B cell lymphoma, as well as anti-CD138-IFN-α against myeloma [17, 55–57]. The gene discussed is IFNA2; the disease is plasma cell myeloma.